2-(5,6-Dimethyl-9-oxoxanthen-1-yl)acetic acid (BioDeep_00000176921)
human metabolite blood metabolite
代谢物信息卡片
2-(5,6-dimethyl-9-oxo-9H-xanthen-1-yl)acetic acid
化学式: C17H14O4 (282.0892)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C)C2=C(C=C1)C(=O)C1=C(CC(O)=O)C=CC=C1O2
InChI: InChI=1S/C17H14O4/c1-9-6-7-12-16(20)15-11(8-14(18)19)4-3-5-13(15)21-17(12)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- M J McKeage, P C Fong, X Hong, J Flarakos, J Mangold, Y Du, C Tanaka, H Schran. Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.
Cancer chemotherapy and pharmacology.
2012 May; 69(5):1145-54. doi:
10.1007/s00280-011-1809-3. [PMID: 22212299] - Leigh Ellis, Preeti Shah, Hans Hammers, Kristin Lehet, Paula Sotomayor, Gissou Azabdaftari, Mukund Seshadri, Roberto Pili. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Molecular cancer therapeutics.
2012 Feb; 11(2):383-92. doi:
10.1158/1535-7163.mct-11-0748. [PMID: 22084164] - Wenkui Li, Hui Lin, Harold T Smith, Francis L S Tse. Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Jul; 879(21):1927-33. doi:
10.1016/j.jchromb.2011.05.012. [PMID: 21680264] - Toyoaki Hida, Motohiro Tamiya, Makoto Nishio, Nobuyuki Yamamoto, Tomonori Hirashima, Takeshi Horai, Hiromi Tanii, Michael M Shi, Ken Kobayashi, Yoshitsugu Horio. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Cancer science.
2011 Apr; 102(4):845-51. doi:
10.1111/j.1349-7006.2010.01839.x. [PMID: 21205086] - Guanjun Cheng, Jing Sun, Zvi G Fridlender, Liang-Chuan S Wang, Lai-Ming Ching, Steven M Albelda. Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
The Journal of biological chemistry.
2010 Apr; 285(14):10553-62. doi:
10.1074/jbc.m109.065631. [PMID: 20118240] - Liang-Chuan S Wang, Lotte Thomsen, Rachel Sutherland, Charu B Reddy, Sofian M Tijono, Chun-Jen J Chen, Catherine E Angel, P Rod Dunbar, Lai-Ming Ching. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
Neoplasia (New York, N.Y.).
2009 Aug; 11(8):793-803. doi:
10.1593/neo.09506. [PMID: 19649209] - M J McKeage, J Von Pawel, M Reck, M B Jameson, M A Rosenthal, R Sullivan, D Gibbs, P N Mainwaring, M Serke, J-J Lafitte, C Chouaid, L Freitag, E Quoix. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
British journal of cancer.
2008 Dec; 99(12):2006-12. doi:
10.1038/sj.bjc.6604808. [PMID: 19078952] - Jing Li, Michael B Jameson, Bruce C Baguley, Roberto Pili, Sharyn D Baker. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Apr; 14(7):2102-10. doi:
10.1158/1078-0432.ccr-07-1475. [PMID: 18381951] - Marie Van de Putte, Yicheng Ni, Peter A M De Witte. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
Oncology reports.
2008 Apr; 19(4):921-6. doi:
NULL. [PMID: 18357376] - Francisco Chung, Jenny Liu, Lai-Ming Ching, Bruce C Baguley. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Cancer chemotherapy and pharmacology.
2008 Mar; 61(3):497-502. doi:
10.1007/s00280-007-0495-7. [PMID: 17473922] - Xiaosong Zhang, Ming Zhao, Michelle A Rudek, Ping He, Bert Vogelstein. Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Jun; 852(1-2):217-22. doi:
10.1016/j.jchromb.2007.01.018. [PMID: 17307035] - M B Jameson, B C Baguley, P Kestell, L Zhao, J W Paxton, P I Thompson, S Waller. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Cancer chemotherapy and pharmacology.
2007 Apr; 59(5):681-7. doi:
10.1007/s00280-006-0322-6. [PMID: 17021822] - Mark J McKeage, Peter Fong, Mark Jeffery, Bruce C Baguley, Phil Kestell, Miroslav Ravic, Michael B Jameson. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006 Mar; 12(6):1776-84. doi:
10.1158/1078-0432.ccr-05-1939. [PMID: 16551862] - Lesley D McPhail, Dominick J O McIntyre, Christian Ludwig, Philip Kestell, John R Griffiths, Lloyd R Kelland, Simon P Robinson. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
Neoplasia (New York, N.Y.).
2006 Mar; 8(3):199-206. doi:
10.1593/neo.05739. [PMID: 16611413] - Peter Kovacic. Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA).
Current medicinal chemistry. Anti-cancer agents.
2005 Sep; 5(5):501-6. doi:
10.2174/1568011054866919. [PMID: 16178775] - Liangli Zhao, Lai-Ming Ching, Philip Kestell, Lloyd R Kelland, Bruce C Baguley. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
International journal of cancer.
2005 Aug; 116(2):322-6. doi:
10.1002/ijc.21005. [PMID: 15800918] - Francisco Chung, Liang-Chuan S Wang, Philip Kestell, Bruce C Baguley, Lai-Ming Ching. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Cancer chemotherapy and pharmacology.
2004 May; 53(5):377-83. doi:
10.1007/s00280-003-0753-2. [PMID: 15060740] - Liangli Zhao, Lai-Ming Ching, Philip Kestell, Bruce C Baguley. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Dec; 9(17):6545-50. doi:
NULL. [PMID: 14695159] - Shufeng Zhou, Philip Kestell, Bruce C Baguley, James W Paxton. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochemical pharmacology.
2003 Jun; 65(11):1853-65. doi:
10.1016/s0006-2952(03)00189-8. [PMID: 12781337] - Bronwyn G Siim, Alan E Lee, Sahar Shalal-Zwain, Frederik B Pruijn, Mark J McKeage, William R Wilson. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer chemotherapy and pharmacology.
2003 Jan; 51(1):43-52. doi:
10.1007/s00280-002-0529-0. [PMID: 12497205] - Francisco Chung, Brian D Palmer, George W Muller, Hon-Wah Man, Phillip Kestell, Bruce C Baguley, Lai-Ming Ching. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Oncology research.
2003; 14(2):75-82. doi:
10.3727/000000003108748621. [PMID: 14649541] - Bruce C Baguley, Lai Ming Ching. DMXAA: an antivascular agent with multiple host responses.
International journal of radiation oncology, biology, physics.
2002 Dec; 54(5):1503-11. doi:
10.1016/s0360-3016(02)03920-2. [PMID: 12459378] - Shufeng Zhou, Philip Kestell, James W Paxton. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Drug metabolism reviews.
2002 Nov; 34(4):751-90. doi:
10.1081/dmr-120015693. [PMID: 12487149] - L Zhao, L-M Ching, P Kestell, B C Baguley. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
British journal of cancer.
2002 Aug; 87(4):465-70. doi:
10.1038/sj.bjc.6600479. [PMID: 12177785] - Shufeng Zhou, Philip Kestell, Bruce C Baguley, James W Paxton. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Investigational new drugs.
2002 Aug; 20(3):281-95. doi:
10.1023/a:1016215015530. [PMID: 12201491] - S F Zhou, M D Tingle, P Kestell, J W Paxton. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Xenobiotica; the fate of foreign compounds in biological systems.
2002 Feb; 32(2):87-107. doi:
10.1080/00498250110092423. [PMID: 11868972] - Shufeng Zhou, Philip Kestell, Malcolm D Tingle, James W Paxton. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer chemotherapy and pharmacology.
2002 Feb; 49(2):126-32. doi:
10.1007/s00280-001-0383-5. [PMID: 11862426] - Liangli Zhao, Philip Kestell, Lai-Ming Ching, Bruce C Baguley. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Cancer chemotherapy and pharmacology.
2002 Jan; 49(1):20-6. doi:
10.1007/s00280-001-0377-3. [PMID: 11855749] - P Kestell, L Zhao, M B Jameson, M R Stratford, L K Folkes, B C Baguley. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Clinica chimica acta; international journal of clinical chemistry.
2001 Dec; 314(1-2):159-66. doi:
10.1016/s0009-8981(01)00692-1. [PMID: 11718691] - S Zhou, R Chin, P Kestell, M D Tingle, J W Paxton. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
British journal of clinical pharmacology.
2001 Aug; 52(2):129-36. doi:
10.1046/j.0306-5251.2001.01438.x. [PMID: 11488768] - S Zhou, J W Paxton, M D Tingle, P Kestell. Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
Journal of chromatography. B, Biomedical sciences and applications.
2001 Jun; 757(2):359-63. doi:
10.1016/s0378-4347(01)00177-3. [PMID: 11417882] - S Zhou, J W Paxton, M D Tingle, P Kestell. Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications.
2001 Jun; 757(2):343-8. doi:
10.1016/s0378-4347(01)00173-6. [PMID: 11417880] - L Zhao, P Kestell, M Philpott, L M Ching, L Zhuang, B C Baguley. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer chemotherapy and pharmacology.
2001 Jun; 47(6):491-7. doi:
10.1007/s002800000267. [PMID: 11459201] - S Zhou, P Kestell, M D Tingle, L M Ching, J W Paxton. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Cancer chemotherapy and pharmacology.
2001 Jun; 47(6):541-4. doi:
10.1007/s002800100285. [PMID: 11459209] - S F Zhou, J W Paxton, M D Tingle, P Kestell, M B Jameson, P I Thompson, B C Baguley. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2001 May; 31(5):277-93. doi:
10.1080/00498250110043544. [PMID: 11491389] - S Zhou, J W Paxton, P Kestell, M D Tingle. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
The Journal of pharmacy and pharmacology.
2001 Apr; 53(4):463-71. doi:
10.1211/0022357011775758. [PMID: 11341362] - S Zhou, J W Paxton, P Kestell, M D Tingle, L M Ching. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Cancer chemotherapy and pharmacology.
2001 Apr; 47(4):319-26. doi:
10.1007/s002800000249. [PMID: 11345648]
